Trial Profile
A Multicenter, Randomized, Double-blind, Active-controlled, 2 Week Treatment, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Sep 2023 Primary endpoint has been met, (Trough FEV1), as per Results published in the Clinical Drug Investigation
- 08 Sep 2023 Results published in the Clinical Drug Investigation
- 21 Oct 2019 Status changed from recruiting to completed.